GlobeNewswire

Mitsubishi Heavy Industries to Acquire Canadair Regional Jet Program from Bombardier Inc.

Share
  • MHI now positioned to transform and lead the underserved regional jet business , with bolster ed customer support services
  • Key step in MHI’s strategy of expanding its aircraft business globally, with a mid-term focus on North America
  • Completes Bombardier’s aerospace transformation and refocus on business aviation

TOKYO and MONTRÉAL, June 25, 2019 (GLOBE NEWSWIRE) -- Mitsubishi Heavy Industries, Ltd (MHI) (TOKYO:7011) and Bombardier Inc (TSX: BBD.B) announced today they have entered into a definitive agreement, whereby MHI will acquire Bombardier’s regional jet program for a cash consideration of $550 million USD, payable to Bombardier upon closing, and the assumption by MHI of liabilities amounting to approximately $200 million USD. Under the agreement, Bombardier’s net beneficial interest in the Regional Aircraft Securitization Program (RASPRO), which is valued at approximately $180 million USD, will be transferred to MHI.

Pursuant to the agreement, MHI will acquire the maintenance, support, refurbishment, marketing, and sales activities for the CRJ Series aircraft, including the related services and support network located in Montréal, Québec, and Toronto, Ontario, and its service centres located in Bridgeport, West Virginia, and Tucson, Arizona, as well as the type certificates.

This acquisition is complementary to MHI’s existing commercial aircraft business, in particular the development, production, sales and support of the Mitsubishi SpaceJet commercial aircraft family. The maintenance and engineering capabilities of the CRJ program will further enhance critical customer support functions, a strategic business area for MHI in the pursuit of future growth.

Seiji Izumisawa, President & CEO of Mitsubishi Heavy Industries Ltd., commented: “As we outlined during the recent Paris Air Show, we are working hard to ensure that we provide new profit potential for airlines and set a new standard for passenger experience. This transaction represents one of the most important steps in our strategic journey to build a strong, global aviation capability. It augments these efforts by securing a world-class and complementary set of aviation-related functions including maintenance, repair and overhaul (MRO), engineering and customer support.”     

Izumisawa concluded, “The CRJ program has been supported by tremendously talented individuals. In combination with our existing infrastructure and resources in Japan, Canada and elsewhere, we are confident that this represents one effective strategy that will contribute to the future success of the Mitsubishi SpaceJet family. MHI has a decades-long history in Canada, and I hope this transaction will result in the expansion of our presence in the country, and will represent a significant step in our growth strategy.”

“We are very pleased to announce this agreement, which represents the completion of Bombardier’s aerospace transformation,” said Alain Bellemare, President and Chief Executive Officer, Bombardier Inc. “We are confident that MHI’s acquisition of the program is the best solution for airline customers, employees and shareholders. We are committed to ensuring a smooth and orderly transition.” 

Bellemare continued: “With our aerospace transformation now behind us, we have a clear path forward and a powerful vision for the future. Our focus is on two strong growth pillars: Bombardier Transportation, our global rail business, and Bombardier Aviation, a world-class business jet franchise with market-defining products and an unmatched customer experience.”

The CRJ production facility in Mirabel, Québec will remain with Bombardier. Bombardier will continue to supply components and spare parts and will assemble the current CRJ backlog on behalf of MHI. CRJ production is expected to conclude in the second half of 2020, following the delivery of the current backlog of aircraft.

Bombardier will also retain certain liabilities representing a portion of the credit and residual value guarantees totaling approximately $400 million USD. This amount is fixed and not subject to future changes in aircraft value, and payable by Bombardier over the next four years.

The transaction is currently expected to close during the first half of 2020 and remains subject to regulatory approvals and customary closing conditions.

The agreement contemplates a reverse break fee payable by MHI under certain circumstances.

About MHI
Mitsubishi Heavy Industries, Ltd. (MHI), headquartered in Tokyo, is one of the world’s leading industrial firms with 80,000 group employees and annual consolidated revenues of around US$38 billion. For more than 130 years, the company has channeled big thinking into innovative and integrated solutions that move the world forward. MHI owns a unique business portfolio covering land, sea, sky and even space. MHI delivers innovative and integrated solutions across a wide range of industries from commercial aviation and transportation to power plants and gas turbines, and from machinery and infrastructure to integrated defense and space systems.

For more information, please visit MHI’s website: www.mhi.com/index.html

About Bombardier
With over 68,000 employees, Bombardier is a global leader in the transportation industry, creating innovative and game-changing planes and trains. Our products and services provide world-class transportation experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.

Headquartered in Montreal, Canada, Bombardier has production and engineering sites in 28 countries as well as a broad portfolio of products and services for the business aviation, commercial aviation and rail transportation markets. Bombardier shares are traded on the Toronto Stock Exchange (BBD). In the fiscal year ended December 31, 2018, Bombardier posted revenues of $16.2 billion US. The company is recognized on the 2019 Global 100 Most Sustainable Corporations in the World Index. News and information are available at bombardier.com or follow us on Twitter @Bombardier.

Bombardier and CRJ are trademarks of Bombardier Inc. or its subsidiaries.

For Information

Olivier Marcil
Vice President
External Communications
Bombardier Inc.
+514 861 2610
Patrick Ghoche
Vice President,
Investor Relations
Bombardier Inc.
+514 861 5727

Corporate Communication Department
Mitsubishi Heavy Industries, Ltd.
mediacontact_global@mhi.co.jp

 

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

AMG Advanced Metallurgical Group N.V. Announces Weekly Share Repurchase Program Transaction Details19.7.2019 21:00:00 CESTPress release

Amsterdam, 19 July 2019 --- AMG Advanced Metallurgical Group N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") reports the repurchases made under its share repurchase program announced on 8 April 2019 and effective from 9 April 2019. Information regarding the progress of the share repurchase program and the aggregate of the transactions (calculated on a daily basis) for the period 15 July 2019 through 19 July 2019 can be found in the bottom half of the table below. Further detailed information regarding both the progress of the share repurchase program and the overall trades made on a daily basis can be accessed via the Investors section of the Company’s website, or clicking the following link: https://amg-nv.com/investors/share-buyback/ Share Repurchase Program Overall progress Share Repurchase Program: Total Repurchase Amount in Shares 2,915,630 Cumulative Repurchase Amount EUR 63,511,098 Cumulative Quantity Repurchased 2,534,054 Cumulative Average Repurchase Price EUR 25.06 Start Date 9 April

Ossur Hf : Össur acquires College Park Industries19.7.2019 17:00:00 CESTPress release

Reykjavik, 19 July 2019 Össur has signed an agreement to acquire College Park Industries, a global provider of lower and upper limb prostheses and supporting services. College Park has over 140 employees and is headquartered in Detroit, USA. Total sales amounted to USD 22 million in 2018. College Park will largely remain independent and continue to diligently serve its customer base, while allowing the combined entity to achieve strategic efficiencies. Össur is committed to growing the College Park brand over the coming years both in the United States and international markets. Together, both companies will be well-positioned to enhance their offerings in both lower and upper limb prosthetics. With this acquisition, Össur hopes to support College Park’s focus on the lower active population and further strengthen its established presence in the upper limb arena. Mutual access to technology and products will enable a more comprehensive product and service offering to customers around the

Norsk Hydro: PÅMINNELSE: Invitasjon - Presentasjon av Hydros resultat for andre kvartal 201919.7.2019 14:43:00 CESTPressemelding

Hydros resultat for andre kvartal 2019 blir offentliggjort tirsdag 23. juli 2019 kl. 07.00. Kvartalsrapporten og presentasjonsmaterialet blir samtidig gjort tilgjengelig på www.hydro.com. Presentasjon i Oslo Det blir holdt en kombinert analytikerpresentasjon og pressekonferanse ved Hydros hovedkontor i Drammensveien 260, Oslo, samme dag, kl. 08.30. Resultatet blir presentert av konsernsjef Hilde Merete Aasheim og konserndirektør for Økonomi og finans Eivind Kallevik. Hele presentasjonen kan sees direkte på web-TV. For påmelding, vennligst send mail til ir@hydro.com. I tillegg til web-TV, hvor det vil være mulig å stille spørsmål skriftlig, vil det også være mulig å ringe inn (ikke mulig å stille spørsmål over telefon). Du melder deg på denne telefonkonferansen ved å ringe: Norge +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sverige +46 (0)8 5033 6574 Brasil +55 11 3181 5427 Tyskland +49 (0)89 20303 5709 Kode: 3104804 Q&A / Telefonkonferanse Det blir holdt en telefonkonferans

Norsk Hydro: REMINDER: Invitation - Hydro’s second quarter results 201919.7.2019 14:43:00 CESTPress release

Hydro's second quarter results 2019 will be released at 07:00 CEST (01:00 AM EDT, 06:00 UK time), on Tuesday July 23, 2019. The quarterly report and presentation slides will be available on www.hydro.com at the same time. Presentation in Oslo Hydro will host a combined analyst and press conference, in English, at its corporate headquarters at Drammensveien 260, Oslo, at 08:30 CEST the same day. The presentation will be held by President and CEO Hilde Merete Aasheim and CFO Eivind Kallevik and can also be seen on web TV. To attend the presentation in Oslo, please register by sending a mail to ir@hydro.com. In addition to the webcast, where it will be possible to ask questions in writing, it will also be possible to dial in (not possible to ask questions over the phone). Dial-in numbers for this conference call are: Norway +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sweden +46 (0)8 5033 6574 Brazil +55 11 3181 5427 Germany +49 (0)89 20303 5709 Confirmation Code: 3104804 Q&A

Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma19.7.2019 14:00:00 CESTPressemelding

STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made a EUR 5 million investment in Forendo Pharma. Claus Andersson, General Partner from Sunstone, joins Forendo Pharma’s Board of Directors. With the investment, Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital Partners. The new financing will enable Forendo Pharma to progress its lead endometriosis program, FOR-6219, an HSD17B1 enzyme inhibitor, into the next phase of clinical studies after the successful completion of its Phase 1a study earlier this year. Endometriosis is a chronic condition that affects many women of reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have